Kyntra Bio, Inc. (LON:0IL8)

Kyntra Bio Statistics

Total Valuation

Kyntra Bio has a market cap or net worth of GBP 22.21 million. The enterprise value is -24.76 million.

Market Cap	22.21M
Enterprise Value	-24.76M

Important Dates

The next estimated earnings date is Monday, February 23, 2026.

Earnings Date	Feb 23, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	4.05M
Shares Outstanding	n/a
Shares Change (YoY)	+1.55%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	2.08%
Owned by Institutions (%)	14.74%
Float	3.58M

Valuation Ratios

The trailing PE ratio is 0.14.

PE Ratio	0.14
Forward PE	n/a
PS Ratio	3.60
PB Ratio	1.71
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.15
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	1.95

Financial Position

The company has a current ratio of 3.71, with a Debt / Equity ratio of 1.11.

Current Ratio	3.71
Quick Ratio	3.56
Debt / Equity	1.11
Debt / EBITDA	n/a
Debt / FCF	-1.14
Interest Coverage	-6.91

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-18.42%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-58.55%
Weighted Average Cost of Capital (WACC)	18.86%
Revenue Per Employee	27,437
Profits Per Employee	713,038
Employee Count	225
Asset Turnover	0.04
Inventory Turnover	2.78

Taxes

Income Tax	-65,467
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -37.39% in the last 52 weeks. The beta is 0.77, so Kyntra Bio's price volatility has been lower than the market average.

Beta (5Y)	0.77
52-Week Price Change	-37.39%
50-Day Moving Average	8.71
200-Day Moving Average	9.12
Relative Strength Index (RSI)	37.03
Average Volume (20 Days)	285

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.13

Income Statement

In the last 12 months, Kyntra Bio had revenue of GBP 6.17 million and earned 160.43 million in profits. Earnings per share was 39.71.

Revenue	6.17M
Gross Profit	-22.58M
Operating Income	-44.01M
Pretax Income	-38.94M
Net Income	160.43M
EBITDA	-43.20M
EBIT	-44.01M
Earnings Per Share (EPS)	39.71

Balance Sheet

The company has 87.77 million in cash and 14.49 million in debt, with a net cash position of 73.28 million.

Cash & Cash Equivalents	87.77M
Total Debt	14.49M
Net Cash	73.28M
Net Cash Per Share	n/a
Equity (Book Value)	13.01M
Book Value Per Share	-3.13
Working Capital	72.50M

Cash Flow

In the last 12 months, operating cash flow was -12.58 million and capital expenditures -133,165, giving a free cash flow of -12.71 million.

Operating Cash Flow	-12.58M
Capital Expenditures	-133,165
Free Cash Flow	-12.71M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-712.89%
Pretax Margin	-630.84%
Profit Margin	2,598.87%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kyntra Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.55%
Shareholder Yield	-1.55%
Earnings Yield	722.22%
FCF Yield	-57.24%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on June 17, 2025. It was a reverse split with a ratio of 0.04.

Last Split Date	Jun 17, 2025
Split Type	Reverse
Split Ratio	0.04

Scores

Kyntra Bio has an Altman Z-Score of -17.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-17.61
Piotroski F-Score	3